brometo de rocurônio
eurofarma laboratÓrios s.a. - brometo de rocurÔnio - bloqueador neuromuscular
brometo de rocurônio
instituto biochimico indÚstria farmacÊutica ltda - brometo de rocurÔnio - bloqueador neuromuscular
brometo de rocurônio
mylan laboratorios ltda - brometo de rocurÔnio - bloqueador neuromuscular
estriol
biolab sanus farmacÊutica ltda - estriol - estrogenos simples
estriopax
brainfarma indÚstria quÍmica e farmacÊutica s.a - estrogenos simples
stele
uniÃo quÍmica farmacÊutica nacional s/a - estrogenos simples
estriol
brainfarma indÚstria quÍmica e farmacÊutica s.a - estrogenos simples
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - agentes antineoplásicos - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.
unirez
uniÃo quÍmica farmacÊutica nacional s/a - brometo de rocurÔnio - bloqueador neuromuscular
estrionil
hipolabor farmaceutica ltda - estriol - hormonios sexuais exclusive ocitocicos